Eli Lilly and Company (NYSE:LLY) Reaches New 12-Month High – Here’s Why

Eli Lilly and Company (NYSE:LLY)’s share price hit a new 52-week high on Tuesday. The company traded as high as $1,304.31 and last traded at $1,300.4580, with a volume of 817,801 shares trading hands. The stock had previously closed at $1,240.34.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Higher analyst target and expected earnings strength: Goldman Sachs raised its price target to $1,413 from $1,371 while maintaining a Buy rating. The firm reportedly expects Eli Lilly to beat third-quarter estimates and raise its outlook, supported by international Mounjaro growth and Zepbound volume gains. Goldman Sachs raises Eli Lilly price target
• Positive Sentiment: International manufacturing expansion: Eli Lilly signed Abu Dhabi agreements involving local packaging and advanced pharmaceutical contract manufacturing for weight-loss medicines. The company also entered a drug-delivery partnership with China’s Metis TechBio valued at up to $1.1 billion, potentially strengthening supply capacity and product-delivery capabilities. Eli Lilly Abu Dhabi packaging deal
• Positive Sentiment: Pipeline expansion: One-year Phase 3 SHINE-2 data showed Omvoh sustained clinical-remission benefits in children with ulcerative colitis, including patients who had previously failed biologic treatments. Regulatory approval could expand Lilly’s inflammatory bowel disease franchise. Pediatric ulcerative colitis data
• Neutral Sentiment: Strong growth, but pricing is a key upcoming issue: Second-quarter revenue increased 48% to approximately $23 billion as medicine volume rose 60%, while realized price per unit declined 13%. Investors will focus on whether continued demand and volume growth can offset pricing pressure when third-quarter results are released on October 29. Eli Lilly volume and pricing analysis
• Negative Sentiment: Competition and valuation risks: Novo Nordisk’s CagriSema produced 25% weight loss in women, reinforcing competitive pressure in the obesity-treatment market. After a substantial rally and record valuation, investors may also be taking profits or demanding stronger evidence that Lilly’s growth can justify its premium multiple. Novo Nordisk CagriSema results

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on the company. Berenberg Bank set a $1,400.00 price objective on Eli Lilly and Company and gave the stock a “buy” rating in a report on Tuesday, September 15th. BMO Capital Markets reissued an “outperform” rating on shares of Eli Lilly and Company in a report on Thursday, October 1st. Wall Street Zen downgraded Eli Lilly and Company from a “buy” rating to a “hold” rating in a research report on Saturday, October 17th. Truist Financial raised their target price on Eli Lilly and Company from $1,370.00 to $1,376.00 and gave the company a “buy” rating in a research report on Friday, August 7th. Finally, Guggenheim lifted their price target on Eli Lilly and Company from $1,273.00 to $1,284.00 and gave the stock a “buy” rating in a research note on Friday, September 18th. One research analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $1,317.93.

Eli Lilly and Company Trading Down 0.9%

The company’s 50 day moving average price is $1,182.84 and its two-hundred day moving average price is $1,116.53. The company has a debt-to-equity ratio of 1.41, a current ratio of 1.35 and a quick ratio of 1.00. The stock has a market capitalization of $1.20 trillion, a PE ratio of 42.68, a P/E/G ratio of 1.71 and a beta of 0.46.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Wednesday, August 5th. The company reported $8.38 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.40 by $1.98. The company had revenue of $22.97 billion during the quarter, compared to analysts’ expectations of $20.82 billion. Eli Lilly and Company had a net margin of 33.53% and a return on equity of 97.83%. Eli Lilly and Company’s revenue was up 47.7% compared to the same quarter last year. During the same quarter in the prior year, the company earned $6.31 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. As a group, analysts expect that Eli Lilly and Company will post 33.56 earnings per share for the current year.

Insider Transactions at Eli Lilly and Company

In related news, EVP Patrik Jonsson sold 6,500 shares of the stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $1,175.10, for a total value of $7,638,150.00. Following the completion of the sale, the executive vice president owned 54,147 shares of the company’s stock, valued at approximately $63,628,139.70. This trade represents a 10.72% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Donald A. Zakrowski sold 2,000 shares of Eli Lilly and Company stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $1,185.01, for a total value of $2,370,020.00. Following the transaction, the chief accounting officer owned 1,526 shares in the company, valued at approximately $1,808,325.26. The trade was a 56.72% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 13,500 shares of company stock worth $15,958,170 in the last ninety days. Insiders own 0.14% of the company’s stock.

Hedge Funds Weigh In On Eli Lilly and Company

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. BlackRock Inc. grew its holdings in shares of Eli Lilly and Company by 1.6% in the second quarter. BlackRock Inc. now owns 67,540,400 shares of the company’s stock valued at $81,009,981,000 after purchasing an additional 1,046,558 shares during the period. State Street Corp raised its stake in Eli Lilly and Company by 1.7% during the second quarter. State Street Corp now owns 36,215,754 shares of the company’s stock worth $43,438,262,000 after purchasing an additional 605,752 shares during the period. Bank of America Corp DE acquired a new position in Eli Lilly and Company in the 2nd quarter valued at about $13,522,666,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in Eli Lilly and Company by 1.9% in the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 7,209,385 shares of the company’s stock valued at $8,647,153,000 after purchasing an additional 137,364 shares during the last quarter. Finally, Jennison Associates LLC boosted its holdings in Eli Lilly and Company by 7.9% in the 2nd quarter. Jennison Associates LLC now owns 5,461,416 shares of the company’s stock valued at $6,550,587,000 after purchasing an additional 400,538 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its major therapeutic areas include diabetes and obesity, oncology, immunology, neuroscience and cardiovascular health.

The company’s portfolio includes Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, Humalog insulin, Taltz for inflammatory diseases, Verzenio for certain breast cancers and Kisunla for early symptomatic Alzheimer’s disease.